Icon closed at $201.65 on Nov 5, down 0.72%, 6.4% below its 52-week closing high. Volume of 1.5M shares was 1.24× its 20-day average (close to normal).
Split-adjusted performance: +22.9% over one month, +61.3% over six months, +23.7% over one year.
Short interest was 3.0M shares at the Oct 15 settlement, up 6.0% from the prior report (3.9% of float, 3.7 days to cover).
Icon is a global contract research organization that provides outsourced clinical development services to pharmaceutical and biotechnology firms. Icon supports clients across late-stage clinical trials through the regulatory approval process and postmarket studies.
What is ICLR's market cap?
$15.11B, based on the Nov 5 close of $201.65.
Does Icon pay a dividend?
No regular cash dividend has been paid in the last year.
How much of ICLR is sold short?
3.0M shares, 3.9% of float, as of Oct 15, 2026.
About Icon
Icon is a global contract research organization that provides outsourced clinical development services to pharmaceutical and biotechnology firms. Icon supports clients across late-stage clinical trials through the regulatory approval process and postmarket studies. Icon's services include clinical trial management, patient recruitment, data analytics, laboratory services, and regulatory consulting. With more than 40,000 employees operating in over 50 countries, the company partners with life sciences firms to run clinical trials and bring new drugs to market.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
